ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BHVN

Biohaven (BHVN)

Biohaven Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:BHVN
DateTimeSourceHeadlineSymbolCompany
02/29/20243:16PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
02/29/20243:05PMPR Newswire (US)Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
01/08/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
01/08/20246:30AMPR Newswire (US)Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and OncoloNYSE:BHVNBiohaven Ltd
01/02/20246:00AMPR Newswire (US)Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
12/01/20233:30PMPR Newswire (US)Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingNYSE:BHVNBiohaven Ltd
11/14/20233:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
11/14/20233:05PMPR Newswire (US)Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
10/16/20236:00AMPR Newswire (US)Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®NYSE:BHVNBiohaven Ltd
10/05/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
10/05/20233:05PMPR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
10/04/20233:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/02/202310:56PMPR Newswire (US)Biohaven Announces Pricing of $225 Million Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
10/02/20238:41PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
10/02/20234:09PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/02/20234:07PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/02/20233:36PMPR Newswire (US)BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARESNYSE:BHVNBiohaven Ltd
10/02/20233:01PMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNYSE:BHVNBiohaven Ltd
09/27/20235:58AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
09/14/20236:00AMPR Newswire (US)Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular AtrophyNYSE:BHVNBiohaven Ltd
09/05/20236:00AMPR Newswire (US)Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal StudiesNYSE:BHVNBiohaven Ltd
07/31/20234:18PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
07/31/20233:29PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
07/31/20238:31AMPR Newswire (US)Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular AtrophyNYSE:BHVNBiohaven Ltd
07/31/20235:59AMPR Newswire (US)Biohaven Reports Second Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
07/28/20233:35PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
07/27/20237:42AMDow Jones NewsBiohaven Told That FDA Won't Review NDA Application for TroriluzoleNYSE:BHVNBiohaven Ltd
07/27/20236:00AMPR Newswire (US)Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate UpdatesNYSE:BHVNBiohaven Ltd
05/31/20236:04AMEdgar (US Regulatory)Current Report Filing (8-k)NYSE:BHVNBiohaven Ltd
05/31/20236:00AMPR Newswire (US)Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D DayNYSE:BHVNBiohaven Ltd
 Showing the most relevant articles for your search:NYSE:BHVN
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com